By targeting BTK and LYN, it blocks both BTK-dependent and -independent BCR-signaling pathways, effectively inhibiting tumor growth of B-NHLs in cell lines and in animal models. Phase I clinical ...

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

Mutations in BRAF, a key component of the mitogen-activated protein kinase (MAPK) pathway ... degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas ...

AACR's achievement awards and lectureships recognize innovation in basic, translational, clinical, and epidemiological cancer research.

B-cell receptor signalling through Bruton’s tyrosine kinase (BTK) is one of the essential growth pathways for CLL. In B-cells, BTK signalling results in the activation of pathways necessary for ...

The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors and BTK degraders was selected for oral presentation Dizal will also ...

The global burden of chronic kidney disease (CKD) is rising, with more than 800 million people affected worldwide. Vascular ...

Pancreatic cancer is a leading cause of cancer-related death, with a five-year survival rate of 13%. The high mortality is ...